医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

SpinalCyte, LLC Receives New Australian Patent for Spinal Disc Tissue Engineering

2015年10月14日 PM11:17
このエントリーをはてなブックマークに追加


 

HOUSTON

SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Australian Patent No. 2013257540, “Methods and Compositions For Repair Of Cartilage Using An In Vivo Bioreactor.” The technology described in the patent involves using an absorbable membrane scaffold to support the growth of new cells populating the nucleus. Other claims provide for a semi-permeable membrane which allows for diffusion of nutrients. The membrane will be used to transfer the intermittent hydrostatic pressure onto the differentiating chondrocyte cells.

“The new Australian Patent broadens our protection internationally and protects our unique technology in one of the fastest growing markets for biologic repair of tissue,” said Pete O’Heeron, Chief Executive Officer. “We are pleased the Australian Commissioner of Patents has recognized the uniqueness of our technology.” SpinalCyte’s patent portfolio includes 11 U.S. and foreign patents issued and directly owned by the company, along with 17 patents pending.

About SpinalCyte, LLC

Based in Houston, Texas, SpinalCyte, LLC is a tissue engineering technology company founded for the purpose of developing an innovative and autologous solution for spinal nucleus replacement using human dermal fibroblasts. The goal of SpinalCyte is to develop a cartilage regeneration technology using autologous dermal cells harvested from the patient. To date, SpinalCyte has been funded entirely by angel investors.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151014005351/en/

CONTACT

SpinalCyte, LLC
Pete O’Heeron, 281.461.6211
CEO
pete@spinalcyte.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease